Bogart Wealth LLC Buys 10,338 Shares of GlaxoSmithKline PLC (GSK)

Bogart Wealth LLC lifted its stake in GlaxoSmithKline PLC (NYSE:GSK) by 40.6% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 35,816 shares of the pharmaceutical company’s stock after purchasing an additional 10,338 shares during the period. GlaxoSmithKline PLC accounts for approximately 1.0% of Bogart Wealth LLC’s holdings, making the stock its 20th largest holding. Bogart Wealth LLC’s holdings in GlaxoSmithKline PLC were worth $1,544,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. FMR LLC boosted its position in shares of GlaxoSmithKline PLC by 5.9% in the 2nd quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock worth $1,079,047,000 after purchasing an additional 1,389,238 shares during the last quarter. Fisher Asset Management LLC boosted its position in shares of GlaxoSmithKline PLC by 4.7% in the 2nd quarter. Fisher Asset Management LLC now owns 12,534,385 shares of the pharmaceutical company’s stock worth $540,483,000 after purchasing an additional 564,519 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of GlaxoSmithKline PLC by 112.1% in the 2nd quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock worth $402,655,000 after purchasing an additional 4,935,900 shares during the last quarter. Hotchkis & Wiley Capital Management LLC boosted its position in shares of GlaxoSmithKline PLC by 4.3% in the 2nd quarter. Hotchkis & Wiley Capital Management LLC now owns 7,847,327 shares of the pharmaceutical company’s stock worth $338,377,000 after purchasing an additional 322,700 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in shares of GlaxoSmithKline PLC by 15.8% in the 1st quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock worth $288,780,000 after purchasing an additional 934,928 shares during the last quarter. Institutional investors and hedge funds own 9.28% of the company’s stock.

Several brokerages recently commented on GSK. Morgan Stanley downgraded GlaxoSmithKline PLC from an “equal weight” rating to an “underweight” rating in a research note on Friday, September 8th. BidaskClub raised GlaxoSmithKline PLC from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 13th. Zacks Investment Research raised GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price objective on the stock in a research note on Tuesday, July 18th. Finally, Argus reaffirmed a “buy” rating and set a $50.00 price objective on shares of GlaxoSmithKline PLC in a research note on Thursday, August 31st. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $44.67.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://ledgergazette.com/2017/10/17/bogart-wealth-llc-buys-10338-shares-of-glaxosmithkline-plc-gsk.html.

GlaxoSmithKline PLC (NYSE:GSK) traded down 0.61% during mid-day trading on Tuesday, hitting $40.61. The company’s stock had a trading volume of 2,937,890 shares. The firm has a market cap of $99.25 billion, a price-to-earnings ratio of 39.35 and a beta of 1.03. The firm has a 50 day moving average of $40.35 and a 200-day moving average of $41.57. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $44.54.

GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.02. The company had revenue of $9.36 billion for the quarter, compared t

Several other large investors also recently bought and sold shares of the company. FMR LLC boosted its position in shares of GlaxoSmithKline PLC by 5.9% in the 2nd quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock worth $1,079,047,000 after purchasing an additional 1,389,238 shares during the last quarter. Fisher Asset Management LLC boosted its position in shares of GlaxoSmithKline PLC by 4.7% in the 2nd quarter. Fisher Asset Management LLC now owns 12,534,385 shares of the pharmaceutical company’s stock worth $540,483,000 after purchasing an additional 564,519 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of GlaxoSmithKline PLC by 112.1% in the 2nd quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock worth $402,655,000 after purchasing an additional 4,935,900 shares during the last quarter. Hotchkis & Wiley Capital Management LLC boosted its position in shares of GlaxoSmithKline PLC by 4.3% in the 2nd quarter. Hotchkis & Wiley Capital Management LLC now owns 7,847,327 shares of the pharmaceutical company’s stock worth $338,377,000 after purchasing an additional 322,700 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in shares of GlaxoSmithKline PLC by 15.8% in the 1st quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock worth $288,780,000 after purchasing an additional 934,928 shares during the last quarter. Institutional investors and hedge funds own 9.28% of the company’s stock.

Several brokerages recently commented on GSK. Morgan Stanley downgraded GlaxoSmithKline PLC from an “equal weight” rating to an “underweight” rating in a research note on Friday, September 8th. BidaskClub raised GlaxoSmithKline PLC from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 13th. Zacks Investment Research raised GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price objective on the stock in a research note on Tuesday, July 18th. Finally, Argus reaffirmed a “buy” rating and set a $50.00 price objective on shares of GlaxoSmithKline PLC in a research note on Thursday, August 31st. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $44.67.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://ledgergazette.com/2017/10/17/bogart-wealth-llc-buys-10338-shares-of-glaxosmithkline-plc-gsk.html.

GlaxoSmithKline PLC (NYSE:GSK) traded down 0.61% during mid-day trading on Tuesday, hitting $40.61. The company’s stock had a trading volume of 2,937,890 shares. The firm has a market cap of $99.25 billion, a price-to-earnings ratio of 39.35 and a beta of 1.03. The firm has a 50 day moving average of $40.35 and a 200-day moving average of $41.57. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $44.54.

GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.02. The company had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. On average, equities research analysts expect that GlaxoSmithKline PLC will post $2.87 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 12th. Stockholders of record on Friday, August 11th were given a dividend of $0.491 per share. This represents a $1.96 dividend on an annualized basis and a dividend yield of 4.81%. The ex-dividend date of this dividend was Wednesday, August 9th. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio is 198.00%.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply